MET and thyroid cancer: The MET pathway is insensitive to targeted drugs (e.g., BRAF or MEK inhibitors) in refractory thyroid cancer, which can cause a BRAFV600E mutation by activating the downstream PI3K/Akt pathway (30, 31).